{"id":"nct:NCT01773928","kind":"trial","title":"Inactivated Split Virus Seasonal Influenza Vaccine (Vero Cell-Derived)","authors":["Alachua Government Services, Inc."],"author_count":1,"year":2013,"published":"2013-01-23","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT01773928","source_url":"https://clinicaltrials.gov/study/NCT01773928","archive_url":"https://space-kitty.com/papers/nct:NCT01773928","updated":"2025-09-11","pmid":null,"pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"The purpose of this study is to determine if a Vero cell-derived trivalent seasonal influenza vaccine produced by the modified manufacturing process: 1. induces immune responses comparable to that produced by the current manufacturing process 2. has an acceptable safety profile compared to a licensed trivalent seasonal influenza vaccine 3. demonstrates consistency of immune response among three different lots.","abstract_license":"ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters","license":"ClinicalTrials.gov terms (attribution, processing date, modifications noted)","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":["Influenza"],"details":{"acronym":null,"status":"COMPLETED","phase":"PHASE3","study_type":"INTERVENTIONAL","enrollment":1928,"sponsor":"Alachua Government Services, Inc.","conditions":["Influenza"],"interventions":["BIOLOGICAL: Vero cell-derived trivalent influenza vaccine manufactured with the modified manufacturing process (VCIV modified)","BIOLOGICAL: VCIV manufactured with the current manufacturing process (VCIV current)","BIOLOGICAL: Fluzone®, licensed trivalent influenza vaccine (TIV)"],"start_date":"2013-01-01","start_date_type":null,"primary_completion_date":"2013-04-01","has_results":true,"data_source":"ClinicalTrials.gov","data_processed":"2026-10-29T09:00:05","modifications":"selected fields only; whitespace normalized; brief summary truncated to 2,000 characters"},"provenance":"clinicaltrials","attribution":"Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.","topics":[{"slug":"gene-cell-therapy","name":"Gene & Cell Therapy","domain_slug":"medicine"}],"cited_in_dossiers":[]}